LARKSPUR, Calif.--(BUSINESS WIRE)--Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through development of potentially best-in-class IL-2 therapeutics, today shared ...

The FDA approved denileukin diftitox (Lymphir), the first novel targeted systemic therapy approved for relapsed/refractory (r/r) cutaneous T-cell lymphoma (CTCL) since 2018, Citius Pharmaceuticals ...

LARKSPUR, Calif.--(BUSINESS WIRE)--Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through development of potentially best-in-class IL-2 therapeutics, today announced ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Patients with bullous pemphigoid treated with IL-2 had ...

Investigator-initiated data from Houston Methodist Hospital showed LD IL-2 reduced proinflammatory factors, both systemically and within the central nervous system, while demonstrating statistically ...

Aulos Bioscience to Present Promising Phase 2 Data for Novel IL-2 Therapeutic AU-007 in Melanoma at AACR Annual Meeting Aulos™ Bioscience, an immuno-oncology company working to revolutionize cancer ...